RxDoctor Payments Data

Nicholas Garn

Optometrist · Zionsville, INNPI 1063433662

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,473 of the $10,705 with a category attached, or 69.8%. 24 manufacturers reported payments, led by Alcon at 30.3% of the total. 2025 is the largest year on record at $4,814, 4.1 times the $1,165 reported in 2019. Among optometrist clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,705in general payments, 2019–2025

Across 231 payments — averaging $46.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Carl Zeiss Meditec USA, Inc.$1K
  • Bausch & Lomb Americas Inc.$1K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$927
  • Coopervision Inc.$658
  • Johnson & Johnson Vision Care, Inc.$595
  • plus $3K from 18 others

What the payments were for

  • Speaking & faculty fees$2,00019%
  • Travel & lodging$1,06810%
  • Food & beverage$7,47370%
  • Education$70%
  • Entertainment$1581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,705 in reported general payments places this provider in the 95th percentile of 1,318 optometrist providers in Indiana.

See all optometrist providers in Indiana

Medicare billing

Part B allowed, 2024
$53,255
Medicare patients
233
Services billed
595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf12$8,802
SimbrinzaBrinzolamide/Brimonidine Tart21$4,211
Loteprednol Etabonate19$3,186
Timolol Maleate28$1,606
Latanoprost69$1,281
Brimonidine Tartrate19$865
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat18$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo$1,223$8,80212 claims
AlconSimbrinza$3,241$4,21121 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$927$3,18619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,318 optometrist providers in Indiana.

Other optometrist in Zionsville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →